Roy Demands Answers On Mifepristone Study, Seeks To End Federal Abortion Funding

Roy Demands Answers On Mifepristone Study, Seeks To End Federal Abortion Funding

Earlier this year, Roy offered an amendment that sought to prohibit federal funds from being used to implement, administer, or enforce the FDA’s January 2023 changes to the mifepristone REMS

Pro-Life Congressman Slams FDA for Delaying Abortion Pill Study

Rep. Chip Roy, R-Texas, is pressing the Food and Drug Administration for answers on the delayed abortion pill study, arguing that the findings could affect conservatives’ efforts to end federal funding for abortion. In a letter obtained by the Daily Signal, Roy asked FDA Acting Commissioner Kyle Diamantas for an update on the publication timeline […]

Congressman Chip Roy demands answers on mifepristone study, seeks end to federal abortion funding * WorldNetDaily * by Virginia Grace McKinnon, The Daily Signal

Fighting Joe Biden's agenda to distribute killing chemical by mail

Rep. Roy Demands Answers from FDA on Delayed Review of Biden’s Mail-Order Abortion Pill Policy

Today, Congressman Chip Roy (TX-21) sent a letter to Food and Drug Administration (FDA) Acting Commissioner Kyle Diamantas demanding answers after the agency indicated that its safety review of mifepristone would not be completed until March 2027, despite assurances that the Biden Administration’s January 2023 modifications to the drug’s dispensing requirements would be

Sen. Hawley engages FDA over concerns about incomplete data in drug study

U.S. Sen. Josh Hawley, R-Missouri, sent a letter to Food and Drug Administration (FDA) Acting Commissioner Kyle Diamantas last week asking whether the agency “is reviewing all relevant data” in the mifepristone safety study it has undertaken.Hawley questioned whether the study is accurately measuring risks to women of the abortion drug, which since 2021 has been available by mail. The FDA halted in-person dispensing requirements during the COVID…

Hawley Seeks Answers About Data Used in FDA Abortion Drug Study

Last week, U.S. Senator Josh Hawley (R-Mo.) sent a letter to Food and Drug Administration (FDA) Acting Commissioner Kyle Diamantas raising concerns that the FDA’s long-promised safety study of the abortion drug mifepristone may be using incomplete data. The letter raises questions about whether the study can adequately assess the effect of the Biden Administration’s 2023 Risk Evaluation and Mitigation Strategy(REMS)—which removed important safeg…